Company intelligence / Profile preview

Sequence Bio

St. John's, Newfoundland and Labrador, Canada

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Sequence Bio develops custom discovery cohorts using genomics, bioinformatics, and patient data, with the aim to discover clinically actionable therapeutic targets more efficiently. Their NL Genome Project is recruiting 10,000 volunteers in Newfoundland for population-scale genetics research. No published clinical results; clinical programs are conducted by pharma partners using Sequence Bio's discoveries

Industry: Drug Discovery Services

Partnerships

LEO Pharma (2022, collaboration for discovery of novel therapeutic targets in dermatology)

Beyond the preview

Go deeper on Sequence Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sequence Bio.

Explore the full profile